(Q37324279)

19 August 2017

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations (English)

1 reference

19 August 2017

0 references

0 references

2

H Wiendl

1 reference

19 August 2017

Multiple Sclerosis Therapy Consensus Group (MSTCG)

1

1 reference

19 August 2017

K V Toyka

3

1 reference

19 August 2017

P Rieckmann

4

1 reference

19 August 2017

R Gold

5

1 reference

19 August 2017

H-P Hartung

6

1 reference

19 August 2017

R Hohlfeld

7

1 reference

19 August 2017

language of work or name

1 reference

29 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

255

1 reference

19 August 2017

1449-1463

1 reference

19 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-008-0061-1

19 August 2017

0 references

cites work

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0061-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0061-1

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0061-1

Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0061-1

IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0061-1

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0061-1

Plasma exchange for severe optic neuritis: treatment of 10 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0061-1

Intravenous Immunoglobulins in MS.

21 January 2018

1 reference

12 December 2020

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study

1 reference

12 December 2020

Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders

1 reference

12 December 2020

Interferon beta in relapsing–remitting multiple sclerosis

1 reference

12 December 2020

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

1 reference

12 December 2020

Melanoma complicating treatment with natalizumab for multiple sclerosis.

1 reference

12 December 2020

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

1 reference

12 December 2020

Human demyelinating disease and the polyomavirus JCV.

1 reference

12 December 2020

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

1 reference

12 December 2020

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

1 reference

12 December 2020

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

1 reference

12 December 2020

Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society

1 reference

12 December 2020

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

1 reference

12 December 2020

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

12 December 2020

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

1 reference

12 December 2020

Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials.

1 reference

12 December 2020

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

12 December 2020

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

12 December 2020

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b

1 reference

12 December 2020

Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.

1 reference

12 December 2020

Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.

1 reference

12 December 2020

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

1 reference

12 December 2020

Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a

1 reference

12 December 2020

The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort

1 reference

12 December 2020

Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis

1 reference

12 December 2020

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

12 December 2020

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

1 reference

12 December 2020

Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis

1 reference

12 December 2020

High dose IVIG in the post partum period for prevention of exacerbations in MS

1 reference

12 December 2020

Mycophenolate mofetil and neurological diseases

1 reference

12 December 2020

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica

1 reference

12 December 2020

Cladribine for multiple sclerosis: review and current status

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event

1 reference

12 December 2020

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

1 reference

12 December 2020

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

1 reference

12 December 2020

Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study

1 reference

12 December 2020

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

12 December 2020

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

12 December 2020

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

12 December 2020

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

1 reference

12 December 2020

Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis

1 reference

12 December 2020

Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis

1 reference

12 December 2020

Visual and motor evoked potentials in the course of multiple sclerosis.

1 reference

12 December 2020

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis

1 reference

12 December 2020

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

12 December 2020

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

12 December 2020

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

1 reference

12 December 2020

Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG.

1 reference

12 December 2020

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging

1 reference

12 December 2020

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

1 reference

12 December 2020

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

1 reference

12 December 2020

MS treatment: new perspectives

1 reference

12 December 2020

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

12 December 2020

Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up

1 reference

12 December 2020

Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study

1 reference

12 December 2020

Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon -1b

1 reference

12 December 2020

Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis.

1 reference

12 December 2020

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

1 reference

12 December 2020

Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis

1 reference

12 December 2020

The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients

1 reference

12 December 2020

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.

1 reference

12 December 2020

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: application in first demyelinating episode.

1 reference

12 December 2020

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis

1 reference

12 December 2020

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

12 December 2020

Anti-adhesion therapies

1 reference

12 December 2020

Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

12 December 2020

Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis

1 reference

12 December 2020

Mitoxantrone: a review of its use in multiple sclerosis

1 reference

12 December 2020

Mycophenolate mofetil in multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis diagnostic criteria: three years later

1 reference

12 December 2020

Mycophenolate mofetil in dermatomyositis: is it safe?

1 reference

12 December 2020

Selective treatment of multiple sclerosis

1 reference

12 December 2020

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

1 reference

12 December 2020

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

12 December 2020

Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies

1 reference

12 December 2020

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

1 reference

12 December 2020

The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice

1 reference

12 December 2020

An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis

1 reference

12 December 2020

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis

1 reference

12 December 2020

[Revision of McDonald's new diagnostic criteria for multiple sclerosis]

1 reference

12 December 2020

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

12 December 2020

An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS

1 reference

12 December 2020

Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis

1 reference

12 December 2020

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

1 reference

12 December 2020

Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese

1 reference

12 December 2020

A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy

1 reference

12 December 2020

Lack of association between antimyelin antibodies and progression to multiple sclerosis.

1 reference

12 December 2020

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

12 December 2020

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

12 December 2020

EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis.

1 reference

12 December 2020

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

1 reference

12 December 2020

A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging

1 reference

12 December 2020

Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

12 December 2020

Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.

1 reference

12 December 2020

10.1007/S00415-008-0061-1

Identifiers

DOI

1 reference

19 August 2017

1 reference